This Week
  • FBI agents have launched a criminal probe involving Bristol Instruments Inc.

  • Dryden Theatre's Malin Kanis hopes to get more young adults in the theater's seats.

  • Doctors and researchers are tapping powerful computers to improve outcomes.

  • Best Lawyers in Rochester guide can help you obtain legal representation.

  • The Business Person of the Year finalists for 2015 are profiled.

  • Ex-Kodak manager Janice Gouldthorpe leads the Genesee Center for the Arts & Education.

Valeant to buy Bausch & Lomb in $8.7B deal

Rochester Business Journal
May 27, 2013

Bausch & Lomb Holdings Inc. has agreed to be acquired by Valeant Pharmaceuticals International Inc. for $8.7 billion in cash.

Laval, Quebec-based Valeant (NYSE: VRX) and Bausch & Lomb announced the definitive agreement today, saying it had been approved unanimously by the board of directors of both companies.

An investor group led by private-equity firm Warburg Pincus LLC will receive roughly $4.5 billion and some $4.2 billion will be used to repay Bausch & Lomb's outstanding debt. Warburg Pincus bought the Rochester business icon for $3.7 billion in September 2007, taking the longtime publicly traded company private.

Bausch & Lomb will keep its name and become a division of Valeant, the companies said. Valeant's existing ophthalmology businesses will become part of the new Bausch & Lomb division, creating a global eye health segment with estimated pro forma 2013 net revenue of more than $3.5 billion.

In an IPO registration statement filed with the Securities and Exchange Commission in March, Bausch & Lomb reported a loss for each of the last three years. Its net losses in 2010-2012 attributable to Bausch & Lomb Holdings were $196 million, $123.9 million and $68.3 million, respectively. Net sales rose from $2.6 billion in 2010 to $3 billion in 2012.

The company filed for the initial public offering after Warburg Pincus reportedly shopped Bausch & Lomb for at least $10 billion without success.

"Valeant's acquisition of our company is a testament to the tremendous value our talented employees have created over the past several years," said Brent Saunders, Bausch & Lomb CEO, in a statement.

After the deal closes, Saunders will join Valeant in an advisory role "to help ensure a seamless transition and integration," the companies said. Bausch & Lomb chairman Fred Hassan will join Valeant's board.

The transaction is expected to close in the third quarter, pending customary regulatory approvals.

Valeant, which plans to borrow $6.7 billion to $7.2 billion to finance the acquisition, expects to achieve at least $800 million in annual cost savings by end of 2014. The companies did not say whether some of those savings would come from cuts to Bausch & Lomb’s current staff.

5/27/13 (c) 2013 Rochester Business Journal. To obtain permission to reprint this article, call 585-546-8303 or email

What You're Saying 

There are no comments yet. Be the first to add yours!

Post Your Own Comment


Not registered? Sign up now!

To Do   Text Size
Post CommentPost A Comment eMail Size1
View CommentsView All Comments PrintPrint Size2
ReprintsReprints Size3
  • E-mailed
  • Commented
  • Viewed
RBJ   Google